Trial Profile
Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 16 Dec 2015 New trial record